Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099268
Status:
COMPLETED
Last Update Posted:
2012-04-23
First Post:
2004-12-10
Brief Title:
Efficacy and Safety of CarbidopaLevodopaEntacapone in Patients With Parkinsons Disease Requiring Initiation of Levodopa Therapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Long Term Double-blind Randomized Parallel-group CarbidopaLevodopa Controlled Multi-center Study to Evaluate the Effect of CarbidopaLevodopaEntacapone in Patients With Parkinsons Disease Requiring Initiation of Levodopa Therapy
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STRIDE-PD
Brief Summary:
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopalevodopaentacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinsons disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None